Y-mAbs Therapeutics (YMAB) announced that naxitamab-gqgk is recommended by the National Comprehensive Cancer Network, NCCN, Clinical Practice Guidelines in Oncology as a NCCN Category 2A treatment option for high-risk neuroblastoma. “We are very pleased with NCCN’s update of the NCCN Guidelines to include naxitamab-gggk. We believe this decision reinforces the importance of naxitimab-gggk as a leading anti-GD2 therapy of choice for physicians treating patients with relapsed/refractory high-risk neuroblastoma,” said Doug Gentilcore, SVP, DANYELZA Business Unit Head.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA
- Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platform
- Y-mAbs Therapeutics downgraded to Underperform from Neutral at BofA
- Y-mAbs downgraded to Underperform at BofA on tough near-term setup
- Y-Mabs Therapeutics: Promising Pipeline and Positive Financial Outlook Justify Buy Rating